Dr.CardioMD said:Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36).
Saving this. It is the first explanation that did not require me to already understand it. Adding it to my notes with a link back to this thread.
Clinical perspective, offered as context rather than as advice. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
LipidDoc_ATL said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
I read this differently from LipidDoc_ATL, on substance rather than tone. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsAdding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.